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This study was designed to compare and evaluate the
presence of engrailed-2 (EN2) protein in urine collected
before and after prostate massage as a diagnostic marker
for prostate cancer (PCa). We analysed and compared 76
urine samples (38 before and 38 after prostate massage)
from the benign group (BPH) and 66 urine samples (33
before and 33 after prostate massage) from patients with
PCa confirmed by prostate biopsy. EN2 levels from the PCa
and men with BPH (age range 50–82) were related to the
tumour stage, Gleason score and prostate-specific antigen.
EN2 levels were determined by enzyme-linked
immunosorbent assay in urine. The median EN2 levels in
urine after prostate massage were significantly different
from those determined in urine before prostate massage
(1.25 ng/ml in the PCa group and 0.34 ng/ml in the BPH).
The mean EN2 levels in PCa patients were 3.76-fold higher
than those in non-PCa patients after prostate massage. The
distinct influence of prostate massage on EN2 levels was
found to be related to the Gleason score and tumour stage.
EN2 may be considered a marker of PCa with certain
limitations, such as those related to tumour staging. The
specificity and sensitivity of the protocol are highly
dependent on prostate massage. European Journal of
Cancer Prevention 24:51–56 © 2014 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
Metabolomic and proteomic profiling of endogenous low-
molecular compounds and proteins, respectively, may be a
way to detect early stages in carcinogenesis, predict cancer
stage or monitor treatment response. Qualitative and
quantitative analysis by metabolomic and proteomic tech-
niques combined with advanced statistical approaches
often enables the development of a metabolic or a pro-
teomic profile that characterizes early changes in specific
organ function in cancers. In urology, metabolomics has
already been used for the interpretation of cancer-related
patterns of the analysed profiles in urogenital cancers (Osl
et al., 2008; Kim et al., 2009; Struck et al., 2013). The serum
prostate-specific antigen (serum PSA) assay and digital
rectal examination (DRE) are used widely as screening
tests and are the starting point for further workup.
However, despite the various procedures utilizing PSA in
the diagnosis of prostate cancer (PCa), such as free-to-total
PSA ratio, PSA velocity, PSA density and age-specific
ranges, all of them have limitations in clinical practice that
prompt an ongoing search for new markers (Downes et al.,
2006). Although sarcosine was initially proposed as a
potential noninvasive diagnostic and prognostic biomarker
for PCa, the most common cancer in men and the leading
cause of cancer-related deaths in the male population of
the USA (Sreekumar et al., 2009; Jiang et al., 2010), further
studies provided evidence that it was not a reliable bio-
marker of PCa invasiveness and aggressiveness (Fenner,
2011; Jentzmik et al., 2011).
These negative data have intensified proteomic research
to find new prostate markers to overcome the PSA-
related limitations. Alpha-methylacyl-coenzyme A race-
mase (AMACR), basic human urinary arginine amidase
(BHUAE), vascular endothelial growth factor (VEGF),
annexin A3 (ANXA3) and prostatic inhibin-like peptide
(PIP) are examples of new potential biomarkers for which
no practical use has been found so far because of their
low sensitivity and specificity. Recent years have wit-
nessed a growing interest in engrailed-2 (EN2).
Typically, EN2 is a homeodomain-containing transcrip-
tion factor (Morgan, 2006). Being members of the Hox
family, EN proteins are multiple regulatory factors at
different stages of development, involving transcriptional
and translational regulation (Shah and Sukumar, 2010).
All the subgroups of EN proteins (EN1–EN5) play cru-
cial roles in development, regulation of numerous
processes including apoptosis, receptor signalling, dif-
ferentiation, motility and angiogenesis. Also, aberrations
in this subgroup's gene expression have been reported in
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abnormal development and malignancy, indicating that
altered expression of the Hox genes could be meaningful
for both oncogenesis and tumour suppression. Recent
findings have shown that the Hox genes are involved in
leukaemia, neuroblastoma and in breast, cervical, lung
and ovarian cancers (Shah and Sukumar, 2010). The Hox
proteins may also be involved in multiple growth factor
pathways that contribute towards hormone-resistant PCa.
Economides and Capecchi (2003) have shown that
HOXB13 is essential for the development of rat prostate.
Moreover, exogenous overexpression of HOXB13 in the
PCa cell line (lnCaP) can suppress hormone-mediated
transactivation of the androgen receptor and conse-
quently prevent the growth of these cells (Jung et al.,
2004a, 2004b; Shah and Sukumar, 2010). In contrast,
aberrant Hox expression may be associated with tumor-
igenesis (Miller et al., 2003).
Most recently, a potential diagnostic application of EN2
transcription factor, which is subsequently re-expressed
in PCa, has been reported (Morgan et al., 2011). A sta-
tistically significant relationship between urinary EN2
level and PCa volume has been identified in an ongoing
study (Pandha et al., 2012). The aim of our study was to
identify and quantify EN2 protein in voided urine and
urine samples collected before and after DRE in patients
with PCa and benign prostatic hyperplasia (BPH). We
showed that EN2 levels determined in urine collected
after digital rectal exam could be helpful in differentiat-
ing patients with PCa from those with BPH.
Materials and methods
Patients and sample collection
Biological samples were collected from patients qualified
for radical prostatectomy (RP) or transurethral resection of
the prostate at the Department of Urology, Jan Biziel
University Hospital in Bydgoszcz, Poland. The patients
were divided into two groups. The cancer group included
patients diagnosed with PCa who qualified for RP and the
BPH group included patients qualified for transurethral
resection of the prostate with no evidence of malignancy,
but diagnosed with benign prostate growth. All the
diagnoses were confirmed by histopathological examina-
tion of the prostate removed from patients with cancer
and by histopathological examination of tissues collected
during resection in patients with BPH. Because of ethical
concerns, concerns about the patients’ health and fear of
potential complications, the patients in the BPH group
were not prostatectomized, which is why histopathologi-
cal examination of the entire prostate was not performed.
Patients with negative digital rectal exam, negative biopsy
results and no malignancy in the resected tissue qualified
for the BPH group. Prostate volume was determined by
the pathologist in the cancer group and by transrectal
ultrasound in the BPH group. Tumour volume was
determined by visual inspection of the percentage of the
specimens affected by cancer. All the histopathological
procedures were performed according to the Protocol for
the examination of specimens from patients with carci-
noma of the prostate gland (Srigley et al., 2009) and Key
issues in handling and reporting radical prostatectomy
specimens (Srigley, 2006). Because the aim of this study
was also to determine whether prostate massage could
affect the EN2 concentration, patients who had under-
gone prostate biopsy or other urological procedures within
1 month before hospital admission were excluded from
participation in this study.
Two urine samples were collected from each patient.
The first sample was collected in the early morning into a
sterile urine container. The second sample was collected
after prostate massage performed by a urologist. Prostate
massage consisted of three sweeps per lobe, depressing
the prostate (0.5–1 cm) in a milking action. Sodium azide
solution was added to the samples to a final concentration
of 1 mmol/l in urine. Samples were divided into smaller
portions and stored immediately after finalizing the pre-
paration protocol at − 80°C until further analysis.
The study was approved by the local ethics committee
(Collegium Medicum Ethics Committee, #KB66/2011).
All patients signed documents for their voluntary parti-
cipation in this study. The sampling was performed
between January 2011 and June 2012.
Determination of EN2
A Human Homeobox protein engrailed-2 ELISA Kit
(EIAab Human Homeobox protein engrailed-2 ELISA
Kit, Wuhan EIAAB Science Co., LTD, Whuan, China,
catalogue number: E1851h) was used for determination
of the human EN2 protein in the urine. Ninety-six-well
plates of an immunoassay kit were precoated with an
antibody specific for the EN2 protein. All urine samples
(100 µl) and standards were transferred to the wells with a
biotin-conjugated polyclonal antibody specific for the
EN2 protein. Avidin conjugated to horseradish perox-
idase was added to each well and incubated.
Enzyme–substrate reaction was terminated by the addi-
tion of sulphuric acid solution. The incubation time and
temperature were followed rigorously according to the
protocol provided by EIAab. Spectrophotometric mea-
surements were performed using a microplate reader set
to 450 nm. Serial dilutions were prepared from a 20 ng/ml
stock solution and the standard curve range was from 0.31
to 20 ng/ml.
Statistical analysis
All statistical calculations and graphical presentation were
performed using Statistica 10 (StatSoft, Tulsa, Oklahoma,
USA) with a medical analysis package. For unpaired
comparison of the cancer and the benign groups, the
Mann–Whitney U-test was used. To test the significance
of the differences between the EN2 level, pathological
stage (pT2a, pT2b, or pT2c) and the tumour grade
(Gleason score= 5, 6, or 7) in the cancer group obtained
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before and after prostate massage, the Wilcoxon test was
used. The receiver operating characteristic (ROC) curves
were generated to determine the diagnostic value of EN2
and PSA.
Results
Overall, 66 urine samples (33× 2) from cancer patients
and 76 urine samples (38× 2) from the benign group were
analysed and compared. The group characteristics
including age, serum PSA levels (mean, median), tumour
volume and EN2 levels (mean, median) are presented in
Table 1. A comparison of age between the two groups
showed no relevant difference (mean age 62 and 65,
respectively). The mean (3.86 ng/ml) and the median
(3.47 ng/ml) values of serum PSA levels were, as expec-
ted, lower in the benign group than in the cancer group
(7.74 and 6.33, respectively; P< 0.001). A total of 22
patients from the benign group had PSA less than 4 ng/
ml, the PSA of 15 patients was between 4 and 10 ng/ml
and one individual had PSA levels higher than 10 ng/ml.
In the cancer group, three patients had PSA levels lower
than 4 ng/ml, 26 patients had PSA levels between 4 and
10 ng/ml and four patients had PSA levels higher than
10 ng/ml.
Enzyme-linked immunosorbent assay was used to
determine the presence of EN2 in urine samples with a
cut-off point of 0.31 ng/ml (specified by the manu-
facturer). EN2 was detected in 18 of the 33 urine samples
of cancer patients and in 18 of the 38 samples from the
benign group in the urine collected before prostate
massage. However, the difference between the groups
did not reach the level of statistical significance
(P> 0.05). The same threshold was used to determine
the presence of EN2 in urine samples collected after
prostate massage. EN2 was detected in 30 of the 33
samples from cancer patients and in 18 of the 38 samples
from the benign group. Statistical comparison of EN2
levels showed that the patients with PCa had higher
levels of EN2, but only in the samples collected after
prostate massage (P< 0.001) (Fig. 1).
A distinct influence of prostate massage on EN2 levels
was observed in the urine when the cancer patients were
subdivided into those with Gleason scores of 5 (n= 8), 6
(n= 13) and 7 (n= 12) (Fig. 2). A significant correlation
was observed between EN2 levels and the tumour grade.
Higher levels of EN2 (median EN2 concentration was
1.98) were identified in the urine from patients with a
Gleason score of 7. Lower median EN2 values in urine
(0.40 and 0.95) were identified in patients with Gleason
scores of 5 and 6, respectively. There was no significant
correlation between the EN2 level and the Gleason score
in urine samples collected before prostate massage. Also,
a similar comparison was performed for the relationship
between urinary EN2 levels and pathological stage
(Fig. 3). The proportion of men with different patholo-
gical stages was 24% for pT2a, 15% for pT2b and 61% for
pT2c. The increasing EN2 level was evidently associated
with tumour stage in urine sample after prostate massage.
Table 1 Patient characteristics: number of patients, age, serum
PSA levels, tumour volume, EN2 levels (ng/ml) in urine before and
after digital rectal examination
Benign Cancer
Number of patients 38 33
Mean age (range) 65 (50–82) 62 (51–79)
Median serum PSA (ng/ml) 3.47 6.33
Mean serum PSA (ng/ml) (range) 3.86 (0.05–10.46) 7.74 (1.09–42.56)
Tumour volume – 28.17 (2.50–90.00)
Mean EN2 (ng/ml) level in urine
collected before DRE (range)
0.50 (0.00–6.92) 0.51 (0.00–3.63)
Median EN2 (ng/ml) level in urine
collected before DRE
0.00 0.00
Mean EN2 (ng/ml) levels in urine
collected after DRE (range)
0.41 (0.00–1.93) 1.54 (0.00–7.25)
Median EN2 (ng/ml) level in urine
collected before DRE
0.34 1.25

















































Group comparison of EN2 concentrations in urine before (a) and after
(b) digital rectal examination (DRE). EN2, engrailed-2. Asterisks,
extreme values; open circles, outliers; open squares, median values.
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However, neither the EN2 level in the urine collected
before prostate massage nor that after prostate massage
was statistically significant. A significant difference
(P= 0.02) was observed only in the more advanced
pathological stages (pT2b and pT2c).
An ROC analysis of urine EN2 concentrations after
prostate massage showed a high diagnostic potential of
EN2 with the area under curve of 0.814, which was larger
than for PSA (0.769) (Fig. 4a and c). Using a cut-off value
of 0.70 ng/ml, EN2 protein is able to predict cancer with a
true positive rate of 79% and a false-positive rate of 19%.
PSA with a cut-off value of 4.01 ng/ml could diagnose
patients with a true positive rate of 90% and a false-
positive rate of 40%. No acceptable statistical parameters
were obtained for the ROC analysis of urine before
prostate massage (Fig. 4b). There was no correlation
between PSA and the biomarker studied (r= 0.0937,
P= 0.4367) (Fig. 5).
Discussion
Despite the numerous potential prostatic biomarkers, so
far most of them have not been found to be useful in
clinical practice (Makarov et al., 2009). As first reported,
the EN2 transcription factor is expressed by PC cell lines
and prostate tumours, but not in the normal prostate
tissue (Morgan et al., 2011). In addition, other studies
have shown that HOXC4-6 and HOXC8 are not normally
expressed in normal prostatic tissue but are upregulated
in biopsy cancer samples (Shah and Sukumar, 2010).
Hence, the aim of our study was to compare the diag-
nostic potential of EN2 as a marker related to its higher
expression and secretion by PCa with commonly used
PSA as a non-PCa-specific marker.
Determination of EN2 in 100 µl of voided urine by
enzyme-linked immunosorbent assay showed that only























































Comparison of the EN2 level in urine collected before (a) and after (b)
digital rectal examination (DRE) in cancer patients subdivided into those
with a Gleason score of 5–7. EN2, engrailed-2. Asterisks, extreme





















































Relationship between urinary EN2 level before (a) and after (b) digital
rectal examination (DRE) and tumour stage. EN2, engrailed-2.
Asterisks, extreme values; open circles, outliers; open squares, median
values.
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the differentiation of PCa and BPH. On the basis
of our results and other results published in different
papers, we can state that there is a connection between
PCa and EN2 levels. We found that EN2 levels were
higher in urine samples collected after prostate massage
in the cancer group and patients with higher concentra-
tions of EN2 were classified higher according to the
Gleason score. It needs to be noted that some patients
diagnosed with benign growth might have had undiag-
nosed PCa. All patients from the BPH group presented
with negative biopsy results for PCa, negative digital
rectal exam results and confirmed BPH on the basis of
the histopathological examination of resected prostate
tissue samples. Still, these methods lack accuracy and
PCa may have been missed. This may explain why
some of the patients presented with high EN2 levels.
Serum PSA levels had a higher true positive rate (PSA
90% compared with EN2 79%), but EN2 had lower
false-positive rate (more false-positive diagnosis using
serum PSA – 40%, compared with 19% false-positive
diagnosis using EN2). Area under the curve showed
more promising results when EN2 concentrations were
used in differentiating cancer and benign disease (0.814
EN2 compared with 0.769). This is why we believe that
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Comparison of the diagnostic potential of EN2 level before (a) and after (b) digital rectal examination (DRE) and PSA (c) using an ROC curve. AUC,
area under the curve; CI, confidence interval; EN2, engrailed-2; PSA, prostate-specific antigen; ROC, receiver operating characteristic.
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However, there are significant limitations to the use of
EN2 as a biomarker for PCa. First, using EN2 would not
eliminate DRE or prostate massage. On the basis of our
result, only urine collected after prostate massage can be
helpful in differentiation of PCa and BPH. Furthermore,
the presently used procedures dependent on the serum
PSA levels have a better true positive rate compared with
EN2 without uncomfortable procedures. There is a need
to carry out a large study that includes cancer, benign
hyperplasia and healthy participants to define EN2 as a
marker for PCa and not only a differentiation tool
between PCa and BPH. Also we believe that combined
prognostic values of both EN2 and serum PSA may
provide more helpful diagnostic information, but this
should be examined more closely on a large scale.
Conclusion
Patients with PCa presented with a higher concentration
of EN2 only in urine collected after prostate massage.
This is a promising result and should be studied more
closely in a larger group of patients that would also
include healthy volunteers.
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